Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets

BACKGROUND: Biologic treatments impose a large financial burden on healthcare payers. Subcutaneous formulations of trastuzumab and rituximab offer administration cost savings relative to the intravenous products through reduced preparation and infusion times. However, intravenous biosimilars have th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Minyoung, Simoens, Steven, Kwon, Taeksang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803676/
https://www.ncbi.nlm.nih.gov/pubmed/33368051
http://dx.doi.org/10.1007/s40259-020-00461-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803676/
https://www.ncbi.nlm.nih.gov/pubmed/33368051
http://dx.doi.org/10.1007/s40259-020-00461-8

Ejemplares similares